Pearsanta, Inc. /
MDNA Life Sciences, Inc.
Pearsanta to acquire MDNA cancer detection assets
What happened
Pearsanta, Inc., a majority owned subsidiary of Aditxt, Inc., completed its acquisition of certain intellectual property and other specified assets relating to MDNA Life Sciences, Inc.’s early cancer detection platform on Jan. 4, 2024.
The consideration includes Pearsanta Preferred Stock with a value intended to equal $25,000,000, subject to the terms described in the filing.
The source
Everything on this page comes from the source below.
Pearsanta to acquire MDNA cancer detection assets
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly